Double-Dose vaccine may protect HIV patients from hepatitis b
NCT ID NCT00670839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who did not respond to earlier hepatitis B shots. The goal was to see if the stronger dose could help their immune system produce enough antibodies to prevent infection. The trial involved 178 participants and compared the two vaccination schedules over several months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre de Soins de l'Infection par le VIH NHC, Hôpitaux Universitaires Strasbourg, 1 place de l'hôpital
Strasbourg, 67091 Cedex, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
- Immune-Boosting cocktail aims to free HIV patients from daily medication